PTGX
Protagonist Therapeutics, Inc
NASDAQ · Healthcare · Biotechnology · US
$134.44
+4.42%Year over year
Reported trailing growth
- Revenue
- +34.8%
- EBITDA
- +110.5%
- EBIT
- +143.3%
- EPS
- +46.8%
- Free cash flow
- +256.3%
- Operating cash flow
- +231.8%
Forward estimates
Based on analyst estimates
- Revenue
- -31.4%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +20.1%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -69.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026